- Home
- TSVT vs ABEO Comparison
TSVT vs ABEO Comparison
Compare TSVT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSVT
- ABEO
- Stock Information
- Founded
- TSVT 2021
- ABEO N/A
- Country
- TSVT United States
- ABEO United States
- Employees
- TSVT N/A
- ABEO N/A
- Industry
- TSVT Biotechnology: Pharmaceutical Preparations
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- TSVT Health Care
- ABEO Health Care
- Exchange
- TSVT Nasdaq
- ABEO Nasdaq
- Market Cap
- TSVT 253.9M
- ABEO 243.9M
- IPO Year
- TSVT N/A
- ABEO 1980
- Fundamental
- Price
- TSVT $4.83
- ABEO $6.46
- Analyst Decision
- TSVT Buy
- ABEO Strong Buy
- Analyst Count
- TSVT 6
- ABEO 3
- Target Price
- TSVT $10.40
- ABEO $18.00
- AVG Volume (30 Days)
- TSVT 341.4K
- ABEO 245.7K
- Earning Date
- TSVT 11-12-2024
- ABEO 11-11-2024
- Dividend Yield
- TSVT N/A
- ABEO N/A
- EPS Growth
- TSVT N/A
- ABEO N/A
- EPS
- TSVT N/A
- ABEO N/A
- Revenue
- TSVT $44,120,000.00
- ABEO N/A
- Revenue This Year
- TSVT N/A
- ABEO N/A
- Revenue Next Year
- TSVT $22.42
- ABEO $7,097.06
- P/E Ratio
- TSVT N/A
- ABEO N/A
- Revenue Growth
- TSVT N/A
- ABEO 147.52
- 52 Week Low
- TSVT $1.54
- ABEO $3.05
- 52 Week High
- TSVT $6.40
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- TSVT 52.75
- ABEO 67.25
- Support Level
- TSVT $4.44
- ABEO $6.06
- Resistance Level
- TSVT $4.83
- ABEO $6.48
- Average True Range (ATR)
- TSVT 0.33
- ABEO 0.33
- MACD
- TSVT -0.00
- ABEO 0.05
- Stochastic Oscillator
- TSVT 56.86
- ABEO 88.98
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.